drugset / Trial / NCT00542711

Bio-availability of a New Liquid Tumeric Extract

NCT00542711 ↗

Phase 1 Withdrawn Hadassah Medical Organization
RandomizedCrossoverOpen-labelTreatment

Summary

Curcumin is a commonly-used spice and food coloring. Evidence suggests that curcumin can suppress tumor initiation, promotion and metastasis in a variety of tumor cell lines. The current available curcumin has low bioavailability restricting the effect of curcumin in non-colon cancer. In this study we plan to test a new liquid tumeric/curcumin extract, Curcumol (patent pending, Israel Patent Application No. 181,121). We predict the bioavailability of the liquid tumeric/curcumin extract will be better compared to the currently used curcumin powder.

Timeline

Start
—
Primary completion
—
Completion
—

Outcome

Outcome not reported

Stopped: “Technical difficulties”

Drugs

EvaluationDrugModalityDoseRoute
Subject Curcumol Unknown 30 unknown —
Subject Curcumol Unknown 50 unknown —
Subject Curcumol Unknown 70 unknown —

Indications

No indication recorded.